Atara Biotherapeutics (ATRA) AI Stock Analysis

• Market Cap: $123.80M
• Dividend Yield: N/A
• Average Volume (3M): 65.37K
• Price to Earnings (P/E): 8.1
• Beta (1Y): 0.67
• Revenue Growth: 51.27%
• EPS Growth: N/A
• Country: US
• Employees: 153
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.32
• Shares Outstanding: 7,210,235
• 10 Day Avg. Volume: 75,965
• 30 Day Avg. Volume: 65,370
• PEG Ratio: 0.01
• Price to Book (P/B): -1.02
• Price to Sales (P/S): 0.77
• P/FCF Ratio: -1.45
• Enterprise Value/Market Cap: 1.93
• Enterprise Value/Revenue: 1.57
• Enterprise Value/Gross Profit: 1.93
• Enterprise Value/Ebitda: 7.85
• 1Y Price Target: $21.50
• Price Target Upside: 36.16% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $17.50 ▲(10.83% Upside)

Atara Biotherapeutics' overall stock score is primarily impacted by its financial instability and recent corporate restructuring. While technical indicators are positive, suggesting potential short-term gains, the company's financial challenges and workforce reduction raise concerns about its long-term stability.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful product development and market penetration, enhancing long-term business prospects.

Profitability Margins

High gross profit margins suggest effective cost management and pricing power, supporting sustainable profitability.

Product Development

Atara's focus on innovative therapies positions it well in the biotech industry, potentially leading to breakthrough treatments and partnerships.

Negative Factors

Financial Instability

Negative equity and financial distress highlight potential solvency issues, posing risks to long-term viability and investor confidence.

Cash Flow Issues

Persistent negative cash flows indicate ongoing cash burn, which could limit the company's ability to fund R&D and growth initiatives.

Workforce Reduction

Significant workforce cuts may impact operational capacity and morale, reflecting underlying financial and strategic challenges.

Atara Biotherapeutics Business Overview & Revenue Model

Company Description

Atara Biotherapeutics (ATRA) is a clinical-stage biotechnology company focused on developing innovative cell therapies for patients with serious diseases, particularly cancer and autoimmune disorders. The company operates primarily in the biopharmaceutical sector, leveraging advanced science to create T-cell therapies that harness the body's immune system to target and eradicate disease. Atara's core products include its lead investigational therapies, which utilize allogeneic T-cell immunotherapy derived from donor cells, aimed at treating various malignancies and chronic viral infections.

How the Company Makes Money

Atara Biotherapeutics generates revenue primarily through collaborations, grants, and clinical trial partnerships. The company may receive milestone payments and royalties from strategic partnerships with larger pharmaceutical companies that help fund its research and development efforts. Significant partnerships can include co-development agreements or licensing deals, where Atara provides its technology and expertise in exchange for financial support and shared profits on future product sales. Additionally, the company may receive funding from government grants or public and private investors, particularly for its innovative therapies that address unmet medical needs.

Atara Biotherapeutics Financial Statement Overview

Summary

Atara Biotherapeutics faces significant financial challenges. Despite a high gross profit margin, the company struggles with low net profit margins and negative revenue growth. The balance sheet shows financial instability with negative equity, and cash flow issues are evident with negative operating and free cash flows.

Income Statement

Atara Biotherapeutics shows a mixed performance in its income statement. The company has a positive gross profit margin of 79.32% TTM, indicating efficient cost management relative to revenue. However, the net profit margin is low at 3.39% TTM, and revenue growth is negative at -5.54% TTM, reflecting challenges in maintaining revenue levels. The EBIT and EBITDA margins are modest at 3.85% and 8.13% TTM, respectively, suggesting limited operational profitability.

Balance Sheet

The balance sheet reveals significant financial instability. The company has a negative stockholders' equity, leading to a negative debt-to-equity ratio of -0.44 TTM, which is concerning. The return on equity is also negative, indicating losses relative to shareholder investments. The equity ratio is not directly calculable due to negative equity, highlighting potential solvency issues.

Cash Flow

Cash flow analysis shows a challenging situation with negative operating and free cash flows. The free cash flow growth rate is negative at -4.98% TTM, and the operating cash flow to net income ratio is -4.39 TTM, indicating cash flow issues relative to earnings. The free cash flow to net income ratio is slightly above 1, suggesting that free cash flow is marginally covering net income.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	151.93M	128.94M	8.57M	63.57M	20.34M	0.00
Gross Profit	124.03M	107.93M	-313.00K	63.57M	-261.66M	-244.65M
EBITDA	30.50M	-75.75M	-266.00M	-222.26M	-331.12M	-300.72M
Net Income	23.40M	-85.40M	-276.13M	-228.30M	-340.14M	-306.62M
Balance Sheet
Total Assets	30.17M	109.10M	165.50M	376.42M	468.13M	588.12M
Cash, Cash Equivalents and Short-Term Investments	13.71M	42.50M	51.73M	242.82M	371.07M	500.66M
Total Debt	58.60M	43.83M	57.87M	71.70M	28.27M	15.03M
Total Liabilities	66.80M	206.38M	264.74M	249.78M	188.51M	125.78M
Stockholders Equity	-36.63M	-97.28M	-99.23M	126.64M	279.61M	462.34M
Cash Flow
Free Cash Flow	-69.80M	-68.96M	-194.20M	-274.62M	-231.10M	-185.27M
Operating Cash Flow	-69.71M	-68.72M	-192.98M	-270.43M	-220.52M	-180.76M
Investing Cash Flow	13.08M	8.62M	123.87M	202.96M	22.26M	-120.73M
Financing Cash Flow	15.77M	59.28M	2.01M	53.08M	103.94M	427.57M

Atara Biotherapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 15.79
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For ATRA, the sentiment is Positive. The current price of 15.79 is above the 20-day moving average (MA) of 15.69, above the 50-day MA of 14.60, and above the 200-day MA of 10.73, indicating a bullish trend. The MACD of 1.06 indicates Negative momentum. The RSI at 65.87 is Neutral, neither overbought nor oversold. The STOCH value of 70.38 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for ATRA.

Atara Biotherapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ATRA	55 Neutral	$123.80M	8.15	―	―	51.27%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADVM	50 Neutral	$96.26M	-0.51	-417.79%	―	-100.00%	-42.12%
TCRX	48 Neutral	$50.83M	-0.80	-76.44%	―	-10.03%	11.06%
ZNTL	46 Neutral	$101.15M	-0.67	-49.18%	―	-33.76%	17.54%
SRZN	43 Neutral	$186.51M	-1.05	―	―	-63.96%	-28.50%
MGNX	41 Neutral	$94.89M	-1.32	-81.13%	―	-9.70%	23.23%

Atara Biotherapeutics Corporate Events

Atara Biotherapeutics Announces Significant Workforce Reduction

On October 6, 2025, Atara Biotherapeutics announced a workforce reduction affecting about 29% of its employees, with the aim of aligning its operations with strategic priorities. The company anticipates incurring approximately $1.3 million in severance and related benefits, with completion expected by January 2026, and further financial details to be disclosed in their upcoming quarterly report.